- Patent Title: Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
-
Application No.: US14351441Application Date: 2012-10-15
-
Publication No.: US09650352B2Publication Date: 2017-05-16
- Inventor: Irving W. Wainer , Ruin Moaddel , Michel Bernier , Carlos A. Zarate , Marc C. Torjman , Michael E. Goldberg , Mary J. Tanga
- Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Service , Cooper Health System , SRI International
- Applicant Address: US DC Washington US NJ Camden US CA Menlo Park
- Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,COOPER HEALTH SYSTEM,SRI INTERNATIONAL
- Current Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,COOPER HEALTH SYSTEM,SRI INTERNATIONAL
- Current Assignee Address: US DC Washington US NJ Camden US CA Menlo Park
- Agency: Cantor Colburn LLP
- International Application: PCT/US2012/060256 WO 20121015
- International Announcement: WO2013/056229 WO 20130418
- Main IPC: C07D295/155
- IPC: C07D295/155 ; C07C225/20 ; C07C237/04 ; C07D295/108 ; C07D295/112 ; C07C229/48 ; C07C237/20 ; C07D295/15
Abstract:
The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
Public/Granted literature
Information query
